Cost-effectiveness analysis of pembrolizumab plus trastuzumab and chemotherapy as first-line treatment for HER2-positive gastric or gastroesophageal junction adenocarcinoma
Haoyu Yang, Weihao Ge, Shuxian Jiang, Xin Lan, Xinting Du · 2026
Read Cost-effectiveness analysis of pembrolizumab plus trastuzumab and chemotherapy as first-line treatment for HER2-positive gastric or gastroesophageal junction adenocarcinoma by Haoyu Yang, Weihao Ge, Shuxian Jiang, Xin Lan, Xinting Du (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13619512.txt.
Description
Haoyu Yang and co-authors weigh the cost and benefit in 2026 of adding a drug called pembrolizumab to standard first line care for a type of stomach cancer. The cancer is driven by a growth signal called HER2.
A large trial had shown the three drug mix helped patients live longer, with and without the disease getting worse. The authors built a survival model from the view of the Chinese health system. It compared life years, quality adjusted life years, and total costs for both plans. The added drug gained just over half a quality adjusted year, but at a very high extra cost. Tests on subgroups and on the model's weak points checked how firm that result was.
Catalog record
| CREATOR | Haoyu Yang, Weihao Ge, Shuxian Jiang, Xin Lan, Xinting Du |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |